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ABSTRACT 
Background. An animal model mimicking all the factors involved in obstructive sleep apnea 
(OSA) is useful for investigating mechanisms because the associated comorbididy usually 
present in such patients is an important limitation. Aim: To test the hypothesis that 
hypoxia/normoxia and the respiratory effort have different effects on the induction of the 
inflammatory response and endothelial dysfunction in an acute rat model of OSA.  
 Methods: Four groups of anesthetized rats were studied (n=8): 1) Sham; 2) Apnea: 
obstructions (15 s each, 60/h, for 3 h); 3) Apnea+O2: obstructions and breathing oxygen-
enriched air to avoid hypoxia and 4) Intermittent hypoxia/normoxia. Inflammatory and 
endothelial mediators were measured as outcomes along with NF-kB in the lung and 
diaphragm..  
Results: TNF-α and IL-1β significantly increased in all groups compared with Sham. NF-kB 
in the lung was increased in Apnea and Hypoxia/Normoxia groups, but not in Apnea+O2 
group. In diaphragm tissue, NF-κB was only significant in Apnea compared to Sham. 
Significant differences were found in the ratio thromboxane-B2/6-keto-Prostaglandin-F1α 
between Apnea and Hypoxia/Normoxia compared to Sham but not in Apnea+O2. 
Conclusions: Oxygen desaturations and respiratory efforts play a role in the induction of 
systemic inflammation but only hypoxia/normoxia induces endothelial dysfunction. These 
data suggest a potential role for oxygen therapy in patients with OSA. 
Word count:  208 
Key words: obstructive apnea, inflammation, endothelial dysfunction, respiratory effort, 
hypoxia, animal model.  
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INTRODUCTION  
Obstructive sleep apnea (OSA) is the most common condition involving sleep-disordered 
breathing, affecting between 4-6% of the population (1). OSA is characterized by intermittent 
episodes of partial or complete obstruction of the upper airway during sleep and these 
disrupt normal ventilation and sleep architecture. OSA is typically associated with excessive 
daytime sleepiness, snoring, and witnessed apneas. This syndrome is also a cardiovascular 
risk factor (2), its association with hypertension (2-4) being one of the most clearly 
determined cardiovascular consequences. 
 
The current evidence available shows that OSA is associated with systemic inflammation 
and endothelial dysfunction (2, 5-15), and this has been considered one of the potential 
mechanisms linking OSA with cardiovascular disease. In most cases, however, the data are 
partial and sometimes even contradictory. Associated comorbidity, such as obesity, may 
represent an important confounding factor, possibly leading to a distortion of the results 
obtained from patient studies. Animal models will therefore be useful for exploring the 
different mechanisms of OSA, as they not only avoid any associated comorbidity but will also 
allow us to analyse the roles of the various factors involved in the syndrome. 
 
In our current research, we are testing the hypothesis that hypoxia/normoxia and respiratory 
effort have different effects on the induction of the inflammatory response and endothelial 
dysfunction present in OSA. To this end, we have used a previously described acute animal 
model of OSA (3 h, in anesthetized animals) that mimics the recurrent upper airway 
obstructions characteristic of this sleep breathing disorder (16). The model avoids the 
associated comorbidiity found in humans and allows us to individualize the various factors 
present in OSA.  Of course, that this acute model can not be completely related to the 
chronic cardiovascular effects. 
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We analysed as outcomes of the different group experiments the circulating levels TNF-α 
and IL-1β, which served as markers of inflammatory response. Furthermore, in order to 
ascertain the source of these pro- inflammatory cytokines, we measured the transcription 
factor nuclear kappa B (NF-κB) in two target tissues involved in recurrent obstructive 
apneas: lung and diaphragm. Additionally, thromboxane-A2 (TxA2) and prostacyclin (PGI2) 
were measured to evaluate the endothelial dysfunction. TxA2 is a powerful starting agent of 
platelet aggregation and a potent vasoconstrictive, whereas, PGI2 has vasodilatadory effects 
and acts against platelet aggregation. An imbalance of vasoconstrictor and vasodilator 
mediators has been implicated in vascular diseases.  
 
A better knowledge of the mechanisms involved in the biological response of OSA might be 
very important, not only for understanding the disease but also for its potential relevance to 
treatment strategy. For instance, in the case that hypoxia/normoxia proved to be the major 
factor responsible for the systemic inflammatory/endothelial response, oxygen administration 
could also play a role in treatment, especially in patients with severe OSA who do not accept 
or tolerate CPAP. 
 
2. MATERIALS AND METHODS 
2.1 Animals 
Pathogen-free male Sprague-Dawley rats, weighing 350-375 g, were obtained from Charles 
River Laboratories (Saint Germain sur L'arbresle, France). The rats were housed in a 
controlled environment and fed rodent chow (A04; Panlab, Barcelona, Spain) and tap water 
ad libitum. This study conformed to European Community (Directive 86/609/EEC) and 
Spanish guidelines for the use of experimental animals and was approved by the institutional 
committees of animal care and research. 
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2.2 Model of recurrent obstructive apneas 
Recurrent obstructive apneas in rats were applied by means of a previously described 
computer-controlled collapsible segment based on a Starling resistor placed in the upper 
airway of the animal (16,17) (Figure 1). Briefly, the collapsible segment consisted of two 
identical cylindrical chambers separated by a circular flexible membrane. The base of one of 
the chambers had a tube connected to a computer-driven source of external pressure that 
produced controlled obstruction of the segment. A tube at the centre of the base of the other 
chamber connected the collapsible segment to the rat trachea. Another tube in this chamber 
wall was open to the atmosphere and acted as a pneumotachograph to measure breathing 
flow. A pressure port in the tube connecting the collapsible segment to the trachea enabled 
us to measure tracheal pressure. Arterial oxygen saturation in the rat leg was monitored by 
pulse oximetry (504 Inc Wauseda, WI, USA). 
 
2.3 Experimental groups 
Experimental animals were randomly divided into four groups (n=8 for each group): Sham, 
Apnea, Apnea+O2 and Hypoxia/Normoxia groups. The animals were anesthetized 
(Urethane 1.2 g/kg, intraperitoneal), a tracheotomy was performed, a cannula (2 mm ID) was 
inserted into the trachea, and the inlet of the cannula was connected to an upper airway 
collapsible segment (16). In the Sham group, no obstructions were applied to the upper 
airway collapsible segment (Figure 2). In the Apnea group, the animals were subjected to 60 
obstructive apneas per hour lasting 15 s each for a period of 3 h. As shown in Figure 2, the 
respiratory efforts during obstructive apneas were three times that of the basal pressure. The 
Apnea+O2 group was treated in the same way as the Apnea group but a rich atmosphere of 
oxygen was applied: the oxygen concentration of the air was adjusted to maintain baseline 
oxygen saturation and avoid desaturations during apneas. The Hypoxia/Normoxia group was 
instrumented by a special device (Figure 1) that allows the induction of hypoxia/normoxia 
periods 60 times per hour. The cycles applied comprised a hypoxic phase (ambient O2 
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concentration 5 %) of 15 s followed by a rapid return to ambient O2 at 21 % for 45 s for a 
period of 3 h (Figure 2). The animals were sacrificed at the end of the experiment by 
exsanguination from the abdominal aorta. 
 
2.4 Biochemical assays in plasma 
The blood samples were put into microcentrifuge tubes containing ETDA, placed on ice and 
centrifuged at 3000 rpm for 15 min. The plasma was collected and frozen at −80°C until 
used. Tumor necrosis factor-α (TNF-α) and Interleukin-1β (IL-1β) concentrations were 
measured by a commercial solid-phase sandwich enzymelinked immuno-sorbent assay 
(ELISA) from R&D Systems (Minneapolis, MN, U.S.A.). Circulating levels of Thromboxane-
B2 (TxB2) and 6-keto-Prostaglandin-F1α (6kPGF1α) were measured with commercially 
available high sensitivity ELISA kits (Cayman Chemical, Tallinn, Estonia). 
 
2.5 Nuclear protein extraction and determination of nuclear factor- B (NF-kB) binding 
activity. 
Samples of lung and diaphragm tissue were obtained immediately after sacrifice, frozen in 
liquid nitrogen and kept at -80 ºC for further studies. For the measurement of NF-κB 
activation, nuclear fractions were prepared from lung and diaphragm tissues using a Nuclear 
Extract Kit (Active Motif, Rixensart, Belgium). Levels of nuclear p65 concentrations were 
determined by TransAMTM NF-κB p65 Chemi kit (Active Motiff, Rixensart, Belgium). 
 
2.6 Statistics 
Data are expressed as mean ± SEM. Statistical analysis was carried out by ANOVA. When 
differences were significant, appropriate post hoc tests, including the Newman-Keuls test 
(GraphPad Software Inc, San Diego, CA, USA), were performed. A value of p< 0.05 was 
considered significant. 
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3. RESULTS 
3.1 Inflammatory biochemical markers  
The inflammatory response was reflected by an increase in TNF-α and IL-1 . Both markers 
showed a significant increase in all the experimental groups, compared to the Sham group 
(Figure 3). There were no differences between groups. These data indicate that respiratory 
effort and recurrent hypoxia/normoxia induce systemic inflammation. 
 
3.2 Nuclear factor-kB binding activity  
NF-kB binding activity was increased in nuclear fractions from lungs in both the Apnea and 
the Hypoxia/Normoxia group compared to the Sham animals. This enhancement in NF-kB 
activity was not observed in the Apnea+O2 group (Figure 4-top). Figure 4-bottom shows NF-
κB activation in nuclear fractions from diaphragm tissue, indicating that, compared to Sham, 
there was a significant increase only in the Apnea group. 
 
3.3 Vascular endothelial markers 
As an indication of endothelial dysfunction, TxB2 and 6kPGF1α were measured in plasma 
samples (Figure 5). The levels of TxB2 showed a significant increase between the Apnea 
and Hypoxia/Normoxia group compared to the Sham group. However, the TxB2 level in the 
Apnea+O2 group did not show a significant increase compared to the Sham group. The 
levels of 6kPGF1α showed a significant decrease between the Apnea and Hypoxia/Normoxia 
group compared to the Sham group. This decrease of 6kPGF1α level was not found in the 
Apnea+O2 compared to the Sham group (Figure 5). An increase in TxB2 accompanied by a 
decrease in the 6kPGF1α, which translates into an increase of the TxB2/6kPGF1α ratio, an 
index of a vasoconstrictor effect, was observed in the Apnea and Hypoxia/Normoxia 
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experimental groups compared to Sham animals. An oxygen-rich atmosphere reversed 
these changes.  
 
4. DISCUSSION 
There is a growing body of evidence in the literature to indicate that OSA is associated with 
increased levels of proinflammatory cytokines, and subsequent increased endothelial 
dysfunction. These could lead to cardiovascular disease (10-15). However, it is not clear to 
what extent hypoxia/normoxia and respiratory effort play a role as mechanisms that trigger 
the inflammatory and endothelial processes in OSA patients. Both stimuli could play an 
important role in the development of cardiovascular diseases. On the one hand, it has been 
reported in experimental models that hypoxia/normoxia without respiratory effort can trigger 
a vascular disease (18). On the other hand, the respiratory effort caused by the upper airway 
obstruction results in large negative swings in intrathoracic pressure that can also trigger 
systemic inflammation. (19). 
 
In our study, we have discriminated between the different challenges that contribute to the 
pathology of OSA in order to identify the importance of these stimuli in the induction of 
systemic inflammation and endothelial dysfunction. The data from our study show that 3 
hours of recurrent obstructive apneas were associated with an increase in inflammatory 
mediators, in line with various studies on OSA patients that have identified increased levels 
of circulating TNF-α and IL-1β. This increase occurs when either the hypoxia/normoxia or 
the respiratory effort appear on their own. We have also observed that apneas and 
hypoxia/normoxia episodes induce endothelial dysfunction, but this was not the case with 
recurrent respiratory efforts (obstructive apneas plus oxygen). 
 
The experimental model allowed us to determine the importance of the different stimuli. It is 
important to take into account that in this experimental model the group of rats with only 
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respiratory efforts maintained a normal oxygen, whereas experimental models of resistive 
breathing are always linked to tissue hypoxia. On the basis of our data, it seems reasonable 
to assume that the activation of inflammatory pathways is caused by the dual presence of 
hypoxia/normoxia and respiratory effort, as has also been suggested by Vassilakopoulos et 
al. (19).  
 
It has been reported that subjects with OSA have a selective activation of NF-κB in 
monocytes compared with control subjects. Thus, the activation of NF-κB may be a 
molecular mechanism implicated in the development of OSA pathology,(7; 12; 20-22) as it is 
well- known that oxidative stress is considered the initial and the major stimulus for NF-κB 
activation, caused by resistive breathing and the hypoxia normoxia episodes (23,24). Our 
results therefore demonstrate an activation of NF-κB triggered by recurrent obstructive 
apneas, in the lung as well as in the diaphragm. Hypoxia/normoxia alone in lung tissue also 
contributes to NF-κB activation; respiratory effort alone does not activate the NF-κB in any of 
these tissues, however. These data suggest that oxygen desaturation plays the major role in 
the activation of NF-κB in the lung, whereas in the diaphragm the activation of NF-κB 
depends on both stimuli being present at the same time. Thus, the increased levels 
observed in TNF-α and IL-1β as a result of respiratory effort alone would have no 
relationship with NF-κB activation in the lung or diaphragm. In this case, TNF-  and IL-1  
plasma levels do not correlate with NF-kB activity from either the lung or the diaphragm. 
These cytokines might be upregulated through a non-NF-kB mediated pathway in both 
tissues, or produced by circulating monocytes, as has been reported in OSA patients (7,20-
22).  
 
Furthermore, OSA patients present an increase in vascular endothelial dysfunction (12-14). 
Dysfunctional endothelium is characterized by an imbalance in the production of vasoactive 
hormones, increased adherence of inflammatory mediators to endothelial cells and 
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hypercoagulability, and it is a known risk factor for cardiovascular events (25). Another point 
that should be considered is the role of the CO2. We have not measured the CO2 levels and 
therefore unable to analyse its role. In fact, the results as regards CO2 are conflicting. On 
the one hand, Fletcher et al. (26) have suggested that exposure to hypercapnia during 
intermittent hypoxia may not be critical because the effect of intermittent hypoxia on diurnal 
blood pressure in rats does not vary according to any increase in the level of carbon dioxide. 
On the other hand, Tamisier et al. (27) have shown that hypercapnic hypoxia does lead to 
greater sympathetic activation than hypocapnic hypoxia.   
 
6kPGF1α has vasodilatadory effects, whereas TxB2 results in vasoconstriction; more 
specifically, since they have markedly opposite effects on vascular tone, the ratio of 
TxB2/6kPGF1α, is an index of vasoconstriction. In this way, it has been reported that patients 
with vascular disease and OSA, show a higher TxB2/6kPGF1α ratio, compared with controls, 
reflecting a predominance of vasoconstrictor activity. This could have cardiovascular 
consequences and suggests that OSA pathology could be associated with an abnormal 
release of prostanoids during sleep (28-29). The results obtained in this study show an 
increase in the TxB2/6kPGF1α ratio induced by recurrent obstructive apneas and 
hypoxia/normoxia. Therefore, these findings suggest a vasoconstrictor effect in apnea and 
hypoxia/normoxia conditions, and this could correlate with our previous studies in the chronic 
animal model, where the animals subjected to 5-s obstructions at a rate of 60 per hour, 6 
h/day for 4 weeks showed higher TxB2/6kPGF1α ratio compared with controls (30).  
 
In summary, in a rat model of sleep apnea we have shown that after only 3 hours any one of 
the tested stimuli – repetitive apneas, oxygen desaturations alone or respiratory efforts alone 
– plays a major role in the induction of an inflammatory process. However, hypoxia/normoxia 
episodes proved to be the main trigger for endothelial dysfunction. Even though this 
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information is derived from an acute animal model, it suggests a possible role for oxygen 
therapy in SAHS treatment, especially in patients where CPAP treatment is not possible. 
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FIGURE LEGENDS  
Figure 1: The system to induce realistic obstructive events in rats is depicted, with the 
general set-up on the top (A). A tracheostomized rat is surrounded by a transparent box. The 
tracheal tube is connected to an upper airway collapsible segment that is able to induce 
obstruction (see below). The box has two large holes. Air is flushed from one of these into 
the sham or apnea groups. A variable FiO2 was applied in the apnea + O2 group. In the 
case of the hypoxia/normoxia group, a number of cycles were applied to form a hypoxic 
phase (ambient O2 concentration 5 %) of 15 s followed by a rapid return to ambient O2 at 21 
% for 45 s. Gas circulates through the box and reaches the other hole. On the bottom (B), 
the collapsible segment is shown. This consists of two chambers and a membrane (M) 
between them. One chamber is connected to a pressure (P) pump. If no pressure is applied, 
the membrane is in its central position (solid line) and there is no obstruction of the trachea. 
When an external pressure is applied, the membrane (dashed line) occludes the tracheal 
port. The other chamber is connected to the tracheostomy tube. Another tube in this clamber 
was open to the atmosphere and acted as pheumotachograph. The pump is controlled by a 
computer-driven source that is able to increase the pressure and move the membrane that 
occludes the thracheostomy. The obstruction can be performed at any frequency and for any 
duration and periodicity. Tracheal pressure and breathing flow can be measured by 
connecting pressure transducers to the corresponding ports in the valve 
Figure 2: Examples of the signals recorded during the experiment. Figure 2A shows sham 
conditions; flow, pressure and the rat’s arterial oxygen saturation (SaO2) exhibited normal 
values. Figure 2B shows that during the apnea, flow was nil owing to valve closure, pressure 
swings in the trachea were markedly increased as a result of breathing effort and the SaO2 
exhibited a transient decrease. Figure 2C shows that during the apnea+O2, flow was nil 
owing to valve closure, pressure swings in the trachea were markedly increased as a result 
of breathing effort but the SaO2 showed no change. Figure 2D shows that during the 
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hypoxia/normoxia, flow was nil owing to valve closure, there were no pressure swings in the 
trachea because of no breathing effort, while the SaO2 exhibited a transient decrease.  
Figure 3: Figure 3A shows a significant increase in plasma levels of Interleukin-1β (IL-1β) 
among the Apnea, Hypoxia/Normoxia and Apnea+O2 groups compared to the Sham group. 
Figure 3B shows significant differences in plasma levels of Tumor necrosis factor-α (TNF-α) 
among the Apnea, Hypoxia/Normoxia and Apnea+O2 groups compared to the Sham group. 
Data are means  SEM of 8 animals per group (*p<0.05 vs Sham group). 
Figure 4: Figure -upper shows a significant increase in the activation of NF-κB in the Apnea 
and the Hypoxia/Normoxia group, compared to the Sham group in nuclear fractions in lung 
tissue. Figure 4-bottom shows a significant in the activation of NF-κB in the Apnea group 
compared to the Sham group in nuclear fractions in diaphragm tissue. Data are means  
SEM of 8 animals per group (*p<0.05 vs Sham group).  
Figure 5: Figure 5-upper shows a significant increase in plasma levels of Thromboxane-B2 
(TxB2) between the Apnea and the Hypoxia/Normoxia groups compared to the Sham group. 
Figure 5-middle shows a significant decrease in plasma levels of 6-keto-Prostaglandin-F1α 
(6kPGF1α) between the Apnea and the Hypoxia/Normoxia groups compared to the Sham 
group. Figure 5-bottom shows the ratio of TxB2/6kPGF1α between the Apnea and the 
Hypoxia/Normoxia groups compared to the Sham group. Data are means  SEM of 8 
animals per group (*p<0.05 vs Sham group). 
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